-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AL-002 in Dementia Associated With Alzheimer’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AL-002 in Dementia Associated With Alzheimer's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AL-002 in Dementia Associated With Alzheimer's Disease Drug Details:...
-
Product Insights
NewPost-Traumatic Stress Disorder (PTSD) – Drugs In Development, 2024
Empower your strategies with our Post-Traumatic Stress Disorder (PTSD) – Drugs In Development, 2024 report and make more profitable business decisions. Post-traumatic stress disorder (PTSD) is a mental health condition that's triggered by experiencing or witnessing a traumatic event. Symptoms include flashbacks, nightmares, and severe anxiety, as well as uncontrollable thoughts about the event. Treatment includes antidepressants, anti-anxiety medications, and cognitive therapy. The Post-Traumatic Stress Disorder (PTSD) drugs in development market research report provide comprehensive information on the therapeutics under development...
-
Product Insights
NewDementia Associated With Alzheimer’s Disease – Drugs In Development, 2024
Empower your strategies with our Dementia Associated With Alzheimer's Disease – Drugs In Development, 2024 report and make more profitable business decisions. Alzheimer's disease (AD) is the most common cause of dementia. AD is a progressive neurodegenerative disorder characterized by cognitive decline, memory loss, and changes in behavior and thinking skills that interfere with daily functioning. Early symptoms may include mild forgetfulness, difficulty recalling recent events or information, and trouble with problem-solving or complex tasks. One of the hallmark features of...
-
Product Insights
NewBipolar Disorder (Manic Depression) – Drugs In Development, 2024
Empower your strategies with our Bipolar Disorder (Manic Depression) – Drugs In Development, 2024 report and make more profitable business decisions. Bipolar disorder, previously known as manic depression, is a mental health condition characterized by extreme mood swings that include emotional highs (mania or hypomania) and lows (depression). These mood shifts can significantly impact a person's ability to function in daily life. The exact cause of bipolar disorder is not fully understood, but it is believed to involve a combination of...
-
Product Insights
NewMajor Depressive Disorder – Drugs In Development, 2024
Empower your strategies with our Major Depressive Disorder – Drugs In Development, 2024 report and make more profitable business decisions. Major Depressive Disorder (MDD) is a common and severe mental health condition characterized by persistent feelings of sadness, hopelessness, and a lack of interest or pleasure in daily activities. Symptoms may include changes in appetite and sleep patterns, fatigue, difficulty concentrating, feelings of worthlessness, and thoughts of death or suicide. Diagnosis is based on the duration and intensity of these symptoms....
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Finerenone in Proteinuria
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Finerenone in Proteinuria report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Finerenone in Proteinuria Drug Details: Finerenone (Kerendia, Firialta) is a nonsteroidal mineralocorticoid. It...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AL-001 in Dementia Associated With Alzheimer’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AL-001 in Dementia Associated With Alzheimer's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AL-001 in Dementia Associated With Alzheimer's Disease Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AL-001 in Alzheimer’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AL-001 in Alzheimer's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AL-001 in Alzheimer's Disease Drug Details: Liprosal is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lazucirnon Hydrochloride in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lazucirnon Hydrochloride in Parkinson's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Lazucirnon Hydrochloride in Parkinson's Disease Drug Details:Lazucirnon hydrochloride (ALK-4290) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Anakinra in Myocarditis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Anakinra in Myocarditis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Anakinra in Myocarditis Drug Details: Anakinra (Kineret) is an immunosuppressant produced in Escherichia...